ADIA Nutrition Inc. Embarks on Nationwide Expansion of Adia Med Satellite Locations
Winter Park, Florida--(Newsfile Corp. - February 24, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a leader in healthcare innovation and regenerative medicine, proudly announces its strategic expansion plan for Adia Med satellite locations across the United States. This initiative aims to make Adia Med's innovative treatments more accessible by partnering with premier Medical Spas dedicated to anti-aging, wellness, and body repair.
ADIA Nutrition Inc. Embarks on Nationwide Expansion of Adia Med Satellite LocationsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10520/241520_adia.jpg
ADIA Nutrition will collaborate with elite Med Spas, leveraging their established infrastructure, reputation, and customer base to introduce Adia Med's advanced treatments. This partnership model creates a beneficial synergy for both partners, enhancing the service offerings of the Med Spas while broadening Adia Med's reach.
The expansion will initially target regions where there's a high demand for longevity, anti-aging, and regenerative treatments, focusing on major cities and affluent suburbs known for their health-conscious demographics. Satellite locations will offer a curated selection of Adia Med's services, including Umbilical Cord Stem Cell (UCB-SC) therapies, stem cell injectables, and other regenerative solutions, which will complement and enhance the existing Med Spa services, providing a comprehensive approach to health and beauty.
To maintain the high standard of care, ADIA Nutrition will provide comprehensive training for Adia's medical professionals alongside rigorous quality control measures. This ensures that the integrity and effectiveness of Adia Med treatments remain consistent across all locations. The expansion will proceed in phases, starting with pilot programs to refine the operational model before a broader rollout, ensuring each step leverages the success of the previous.
Investment and Growth Potential
By partnering with Med Spas, Adia Med can significantly expand its market presence with reduced overhead costs, offering Adia a model with lower risk and high scalability. This approach introduces multiple revenue streams through service fees, royalties, and potential equity interests, creating a robust financial framework. The synergy between Adia Med and its Med Spa partners not only increases market penetration but also enhances revenue potential by tapping into an already engaged clientele interested in wellness and anti-aging solutions.
Larry Powalisz, CEO of ADIA Nutrition, stated, "Here is a piece of the roadmap of our expansion as promised. This expansion into satellite locations through strategic partnerships with premier Med Spas is a testament to our commitment to making our life-changing therapies more accessible. We believe this model not only accelerates our growth but also aligns perfectly with our vision for regenerative medicine."
This strategic expansion lays the groundwork for future product and service introductions, utilizing the existing network for rapid market adoption and providing valuable feedback for continuous innovation. ADIA Nutrition invites current and potential shareholders to follow this exciting development, promising to redefine healthcare accessibility and efficacy.
Larry Powalisz also highlighted that the success of this initiative stems from the mutual benefits it offers; every successful Med Spa will significantly benefit from Adia Med's ability to help existing patients and attract new ones, bolstered by a generous commission structure that ensures financial benefits for all parties involved.
For inquiries or further information, Med Spas and medical professionals are encouraged to contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.comWebsite: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/241520
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
GlucoGuard Receives $43 Million Enterprise Valuation Research Report
Del Mar, California--(Newsfile Corp. - June 10, 2025) - Harbinger Research, LLC an independent equity research firm with a focus on the small cap and microcap stocks, announced today that it has published a new research report on American Diversified Holdings Corporation/GlucoGuard (OTC Pink: ADHC). The report includes a valuation analysis, multi-year financial forecast model, and a value estimate of the Company and its shares. The report puts a fully diluted price target of .0012 equivalent to a $43 million enterprise valuation, assuming full dilution for required developmental capital at the current stock price. As the stock price increases, the dilution would decline accordingly raising the price target. Currently, ADHC is working with Investment Partners on Capital Formation that will benefit the enterprise valuation model utilizing non-dilutive or controlled dilutive financial models. As the development process continues further Intellectual Property filings with the USPTO is anticipated further enhancing GlucoGuards' valuation proposition. A main catalyst for GlucoGuards valuation will be fully described in future releases with a full analysis of the artificial intelligence and predictive learning aspect of the Bio Tracking and recording of blood Glucose levels. To access the research report, please visit the Harbinger Research website at: 2023-06-02 American Diversified Holdings Corp. Coverage Initiation Report ( "Management views the $43 M enterprise value to be conservative due to ability of the GlucoGuard technology to meet the unmet need of hypoglycemia and the severe problems of "Death in Bed"," commented ADHC. "Additionally, this report does not incorporate GlucoGuards' AI and Predictive learning software components and related IP due to its developing nature," concluded ADHC. Key Aspects of the Report 537mm Diabetic Patients Worldwide. 37 mm Diabetic Patients In the US. 3.7 Type 1 Diabetics in the US. 190k to 380K Potential Patients in the US. a potential market of $360 MM to $720MM in revenues. IN ADDITIONAL NEWS ADHC is in negotiations for a strategic partnership to license the GlucoGuard Technology to the Eurpean Union for upfront cash payments, milestone cash payments and cash payment royalties from revenues. Arete Biosciences development contract has been initially funded and is expected to expand into patient studies. ADHC 6-15-25 Quartely disclosure filing is expected to be filed this week ahead of the deadline. Dexcom APP integration and AI software system is under review and should be proceeding to the next phase in the near term. Patent Counsel is updating GlucoGuards' IP with the USPTO. Shareholders should anticipate and continual stream of announcements on these developments and more in the near future. About Harbinger Research, LLC Harbinger Research, LLC is one of a new breed of issuer-sponsored research boutiques, providing unbiased equity research coverage to smaller issuers that cannot attract research coverage from traditional brokerage firm's research departments. Our mission is to help both investors and public issuers by improving the availability of issuer information and by providing sound, unbiased analysis of our issuer clients' businesses, industries, and current market valuation. The policies of Harbinger Research, LLC require that all personnel strictly adhere to the CFA Institute's Code of Ethics and Standards of Professional Conduct, and its Best Practice Guidelines Governing Analyst / Corporate Issuer Relations. Please see for more information. To view our disclosures and disclaimers, or for more information, visit Harbinger Research, LLC Brian Connell, CFA Senior Research Analyst brian@ ABOUT GLUCOGUARD GlucoGuard, a Division of American Diversified Holdings Corporation is a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology. For more information, visit: Contact: Phone: 817-525-0057Email: info@ To view an enhanced version of this graphic, please visit: To view an enhanced version of this graphic, please visit: ABOUT AMERICAN DIVERSIFIED HOLDINGS CORPORATION John Cacchioli, CEO American Diversified Holdings Corporation Telephone: (212) 537-5900 INVESTOR HOTLINE 858-325-7098 Email: JC@ ; ADHCInvestor@ SOCIAL MEDIA TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC. SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise. SOURCE: American Diversified Holdings Corporation To view the source version of this press release, please visit
Yahoo
8 hours ago
- Yahoo
Adia Nutrition Inc. to Present at the Life Sciences Virtual Investor Forum June 11th
Adia Nutrition Inc. invites individual and institutional investors, as well as advisors and analysts, to attend online at WINTER PARK, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, focused on advancing regenerative medicine through stem cell therapies and nutritional solutions, today announced that Larry Powalisz, Chief Executive Officer, will present live at the Life Sciences Virtual Investor Forum, hosted by on June 11th, 2025. DATE: June 11th, 2025TIME: 2:00 PM ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12-13 This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Recent Company Highlights Opened Adia Med clinic in Winter Park, FL, in January 2025, offering Autologous Hematopoietic Stem Cell Transplantation (aHSCT) for multiple sclerosis and autoimmune conditions. Expanded regenerative therapies with two premier stem cell and exosome products, Adia Vita, an FDA-registered 361 HCT/P umbilical cord stem cell product containing 100 million viable cells and 3 trillion exosomes per unit and AdiaLink, an FDA-registered 361 HCT/P exosome product containing 3.5 trillion exosomes per unit. Secured licensing agreements to meet global demand for Adia Med's regenerative therapies, announced June 9, 2025. Established subsidiaries Adia Labs LLC and Adia Med of Tinton Falls LLC to distribute and provide innovative treatments nationwide. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings, and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. Virtual Investor ConferencesJohn M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group(212) 220-2221johnv@
Yahoo
a day ago
- Yahoo
TALON METALS ANNOUNCES UPSIZED $39 MILLION FINANCING COMPRISED OF $25 MILLION BROKERED PRIVATE PLACEMENT AND CONCURRENT $14 MILLION NON-BROKERED PRIVATE PLACEMENT
/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ ROAD TOWN, Tortola, British Virgin Islands, June 9, 2025 /CNW/ - Talon Metals Corp. (TSX: TLO) (OTC Pink: TLOFF) ("Talon" or the "Company") is pleased to announce that as a result of strong investor demand, the Company has amended its agreement with Canaccord Genuity Corp. ("Canaccord Genuity") on behalf of a syndicate of underwriters (the "Underwriters") to increase the size of its previously announced "bought deal" private placement of units of the Company (the "LIFE Units") to raise gross proceeds of $25,300,000 (the "LIFE Offering"), consisting of 115,000,000 LIFE Units at a price of $0.22 per LIFE Unit (the "Offering Price"). Concurrent with the LIFE Offering, the Company plans to complete a non-brokered private placement of up to 62,227,274 units of the Company (the "Non-LIFE Units" and, together with the LIFE Units, the "Units") at the Offering Price per Non-LIFE Unit for aggregate gross proceeds of up to approximately $13,690,000 (the "Non-LIFE Offering" and, together with the LIFE Offering, the "Offerings"). The Non-LIFE Units will be issued on the same terms as the LIFE Units. The Non-LIFE Units may be offered to purchasers resident in Canada pursuant to applicable prospectus exemptions, other than the Listed Issuer Financing Exemption (as defined below), in accordance with applicable laws, and may also be offered in other qualifying jurisdictions outside of Canada on a private placement basis pursuant to relevant prospectus or registration exemptions in accordance with applicable laws. Any securities issued under the Non-LIFE Offering to purchasers resident in Canada will be subject to a hold period in accordance with applicable Canadian securities laws, expiring four months and one day following the issue date of the Non-LIFE Units. The Non-LIFE Offering will be completed with certain directors, officers and affiliates of Pallinghurst Nickel International Ltd. Each Unit will be comprised of one common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a "Warrant"). Each Warrant will entitle the holder thereof to acquire one Common Share (a "Warrant Share") at a price of $0.28 per Warrant Share for a period of 36 months from the closing of the LIFE Offering or Non-LIFE Offering, as applicable. In the event that the closing price of the Common Shares on the Toronto Stock Exchange (the "TSX") (or such other Canadian stock exchange on which the Common Shares are then listed) for twenty (20) consecutive trading days exceeds $0.56, the Company may, within 10 business days of the occurrence of such event, deliver a notice (including by way of a news release) to the holders of Warrants accelerating the expiry date of the Warrants to the date that is 30 days following the date of such notice. The LIFE Units will be offered pursuant to Part 5A of National Instrument 45-106 – Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the "Listed Issuer Financing Exemption"), to purchasers resident in Canada (other than the province of Québec), and in other qualifying jurisdictions outside of Canada that are mutually agreed to by the Company and the Underwriters on a private placement basis pursuant to relevant prospectus or registration exemptions in accordance with applicable laws. The securities issued under the LIFE Offering to Canadian subscribers will not be subject to a hold period in Canada. There is an amended and restated offering document related to the LIFE Offering (the "Offering Document") that can be accessed under the Company's profile on SEDAR+ at and on the Company's website at Prospective investors should read the Offering Document before making an investment decision. The Company intends to use the net proceeds from the Offerings to advance the Tamarack Nickel Project and for general and administrative expenses and working capital purposes, as further described in the Offering Document. The Offerings are expected to close on or about June 19, 2025, or such other date as the Company and Canaccord Genuity may agree (the "Closing Date"). The Non-LIFE Offering may close on a date subsequent to or prior to the closing date of the LIFE Offering at the discretion of the Company. The Offerings are subject to the Company receiving all necessary regulatory approvals, including the approvals of the TSX. The closing of the LIFE Offering is not conditional upon closing of the Non-LIFE Offering, and the closing of the Non-LIFE Offering is not conditional upon closing of the LIFE Offering. The Units (and the underlying securities) to be offered pursuant to the Offerings have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About Talon Talon is a TSX-listed base metals company in a joint venture with Rio Tinto on the high-grade Tamarack Nickel-Copper-Cobalt Project located in central Minnesota. Talon's shares are also traded in the US over the OTC market under the symbol TLOFF. The Tamarack Nickel Project comprises a large land position (18km of strike length) with additional high-grade intercepts outside the current resource area. Talon has an earn-in right to acquire up to 60% of the Tamarack Nickel Project and currently owns 51%. Talon is focused on (i) expanding and infilling its current high-grade nickel mineralization resource prepared in accordance with NI 43-101 to shape a mine plan for submission to Minnesota regulators, and (ii) following up on additional high-grade nickel mineralization in the Tamarack Intrusive Complex. Talon has a neutrality and workforce development agreement in place with the United Steelworkers union. Talon's Beulah Mineral Processing Facility in Mercer County was selected by the US Department of Energy for US$114.8 million funding grant from the Bipartisan Infrastructure Law and the US Department of Defense awarded Talon a grant of US$20.6 million to support and accelerate Talon's exploration efforts in both Minnesota and Michigan. Talon has well-qualified experienced exploration, mine development, external affairs and mine permitting teams. Forward-Looking Statements This news release contains certain "forward-looking statements". All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements reflect the current expectations and beliefs of the Company based on information currently available to the Company. Such forward-looking statements include statements relating to the Offerings, including the completion and anticipated timing for completion of the Offerings, the potential size of the Offerings, the Company's intended use of the net proceeds of the Offerings, the receipt of all necessary regulatory approvals, including the approvals of the TSX, and the Company's exploration and development plans. Forward-looking statements are subject to significant risks and uncertainties and other factors that could cause the actual results to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. SOURCE Talon Metals Corp. View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
